[CAS NO. 31121-93-4]  Ibuprofensodium

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [31121-93-4]

Catalog
HY-78131C
Brand
MCE
CAS
31121-93-4

DESCRIPTION [31121-93-4]

Overview

MDL-
Molecular Weight228.26
Molecular FormulaC13H17NaO2
SMILESO=C(O[Na])C(C)C1=CC=C(CC(C)C)C=C1

For research use only. We do not sell to patients.


Summary

Ibuprofen ((±)-Ibuprofen) sodium is an orally active, selective COX-1 inhibitor with an IC 50 value of 13 μM. Ibuprofen sodium inhibits cell proliferation, angiogenesis, and induces cell apoptosis . Ibuprofen sodium is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen sodium can be used in the research of pain, swelling, inflammation, infection , immunology, cancers [1] [2] [5] [8] .


IC50 & Target

COX-1

13 μM (IC 50 )

COX-2

370 μM (IC 50 )


In Vitro

Ibuprofen sodium (24 h) inhibits COX-1 and COX-2 activity with IC 50 values of 13 μM and 370 μM [1] .
Ibuprofen sodium (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line) [2] .
Ibuprofen sodium (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell [2] .
Ibuprofen sodium (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells [3] .
Ibuprofen sodium (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process [4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [2]

Cell Line: AGS cells
Concentration: 100-1000 μM
Incubation Time: 24 h, 48 h
Result: Inhibited AGS cell viability with IC 50 values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining , 48 h) and 408 μM (neutral red assay, 48 h).

In Vivo

Ibuprofen sodium (fed in animal feedings, 300 mg/kg, 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer [5] .
Ibuprofen sodium (subcutaneous injection, 60 mg/kg, every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin‑induced peripheral neuropathy [6] .
Ibuprofen sodium (oral administration, 20 mg/kg, every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise [7] .
Ibuprofen sodium (oral administration, 35 mg/kg, twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection [8] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum) [5]
Dosage: 300 mg/kg, daily for 14 days
Administration: Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)
Result: Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells.
Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.
Animal Model: Oxaliplatin‑induced peripheral neuropathy [6]
Dosage: 60 mg/kg, every second day for 15 days
Administration: Subcutaneous injection
Result: Lowered sensory nerve conduction velocity (SNCV).

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02417506 Vedic Lifesciences Pvt. Ltd.|Enovate Biolife Pvt Ltd
Osteoarthritis of Knee
August 2014 Not Applicable
NCT00092755 Organon and Co
Osteoarthritis
April 9, 2003 Phase 3
NCT00707057 SCOLR Pharma, Inc.|AAIPharma|Jean Brown Research
Pain|Post-Operative Pain|Third Molar Extraction
June 2008 Phase 3

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


Solvent & Solubility

In Vitro:

H 2 O : ≥ 100 mg/mL ( 438.10 mM )

DMSO : 20.83 mg/mL ( 91.26 mM ; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.3810 mL 21.9048 mL 43.8097 mL
5 mM 0.8762 mL 4.3810 mL 8.7619 mL
10 mM 0.4381 mL 2.1905 mL 4.3810 mL
* Please refer to the solubility information to select the appropriate solvent.


Synonyms

Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-, sodium salt (1:1)
Hydratropic acid, p-isobutyl-, sodium salt
Benzeneacetic acid, α-methyl-4-(2-methylpropyl)-, sodium salt
Sodium ibuprofen
2-(4-Isobutylphenyl)propionic acid sodium salt
Ibuprofen sodium salt
Ibuprofen sodium
Sodium 2-(4-isobutylphenyl)propionate
α-Methyl-4-(2-methylpropyl)benzeneacetic acid sodium salt